Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v6-EN Version v3-EN
Language English English
Date Updated 2020-03-06 2020-03-04
Drug Identification Number 02472988 02472988
Brand name KEVZARA KEVZARA
Common or Proper name KEVZARA PEN 200MG/1.14ML KEVZARA PEN 200MG/1.14ML
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients SARILUMAB SARILUMAB
Strength(s) 200MG 200MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS
Packaging size 2 pre-filled pens 2 pre-filled pens
ATC code L04AC L04AC
ATC description IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2020-03-03 2020-03-03
Actual start date
Estimated end date 2020-03-13 2020-03-13
Actual end date 2020-03-05
Shortage status Resolved Actual shortage
Company comments Production Delay: The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy Production Delay: The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy
Health Canada comments